Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Mar;34(3):285-301.
doi: 10.1007/s40273-015-0340-5.

Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation

Monika Wagner  1 , Hanane Khoury  2 , Jacob Willet  3 , Donna Rindress  2 , Mireille Goetghebeur  2   4
Affiliations

Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation

Monika Wagner et al. Pharmacoeconomics. 2016 Mar.

Abstract

Background: The multiplicity of issues, including uncertainty and ethical dilemmas, and policies involved in appraising interventions for rare diseases suggests that multicriteria decision analysis (MCDA) based on a holistic definition of value is uniquely suited for this purpose. The objective of this study was to analyze and further develop a comprehensive MCDA framework (EVIDEM) to address rare disease issues and policies, while maintaining its applicability across disease areas.

Methods: Specific issues and policies for rare diseases were identified through literature review. Ethical and methodological foundations of the EVIDEM framework v3.0 were systematically analyzed from the perspective of these issues, and policies and modifications of the framework were performed accordingly to ensure their integration.

Results: Analysis showed that the framework integrates ethical dilemmas and issues inherent to appraising interventions for rare diseases but required further integration of specific aspects. Modification thus included the addition of subcriteria to further differentiate disease severity, disease-specific treatment outcomes, and economic consequences of interventions for rare diseases. Scoring scales were further developed to include negative scales for all comparative criteria. A methodology was established to incorporate context-specific population priorities and policies, such as those for rare diseases, into the quantitative part of the framework. This design allows making more explicit trade-offs between competing ethical positions of fairness (prioritization of those who are worst off), the goal of benefiting as many people as possible, the imperative to help, and wise use of knowledge and resources. It also allows addressing variability in institutional policies regarding prioritization of specific disease areas, in addition to existing uncertainty analysis available from EVIDEM.

Conclusion: The adapted framework measures value in its widest sense, while being responsive to rare disease issues and policies. It provides an operationalizable platform to integrate values, competing ethical dilemmas, and uncertainty in appraising healthcare interventions.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Adapted EVIDEM MCDA framework: (a) quantitative MCDA model (with hierarchical structure and weighting method); and (b) contextual criteria for qualitative appraisal. MCDA multicriteria decision analysis; PRO patient-reported outcome
See this image and copyright information in PMC

Comment in

References

    1. EURORDIS. Rare diseases: understanding this public health priority. EURORDIS. 2005. Available at: http://www.eurordis.org/publication/rare-diseases-understanding-public-h.... Accessed 21 Oct 2013.
    1. Barrera LA, Galindo GC. Ethical aspects on rare diseases. Adv Exp Med Biol. 2010;686:493–511. doi: 10.1007/978-90-481-9485-8_27. - DOI - PubMed
    1. Kole A, Faurisson F. Rare diseases social epidemiology: analysis of inequalities. Adv Exp Med Biol. 2010;686:223–250. doi: 10.1007/978-90-481-9485-8_14. - DOI - PubMed
    1. Beutler E. Lysosomal storage diseases: natural history and ethical and economic aspects. Mol Genet Metab. 2006;88(3):208–215. doi: 10.1016/j.ymgme.2006.01.010. - DOI - PubMed
    1. Gomez-Rubio V, Lopez-Quilez A. Statistical methods for the geographical analysis of rare diseases. Adv Exp Med Biol. 2010;686:151–171. doi: 10.1007/978-90-481-9485-8_10. - DOI - PubMed

Publication types